Review article · 2024 · Open access

CAR immunotherapy in autoimmune diseases: promises and challenges

Jingjing Yu, Yi Yang, Zhanjing Gu, Min Shi, Antonio La Cava, Aijing Liu

Frontiers in Immunology, 15, 1461102 · Published 1 October 2024 · DOI 10.3389/fimmu.2024.1461102

Open PDFView at the publisherCite this paper

In brief

“CAR immunotherapy in autoimmune diseases: promises and challenges” is a 2024 review article by Jingjing Yu and 5 co-authors, published in Frontiers in Immunology. OpenAlex counts 39 citations as of 21 November 2026. It is open access under a CC BY licence: the full text is free to read at Frontiers in Immunology.

Citations
39
Most cited in
2025 (19)
Field-weighted impact
1.74
References
66
Authors
6

Abstract

In recent years, the use of chimeric antigen receptor (CAR)-T cells has emerged as a promising immunotherapy in multiple diseases. CAR-T cells are T cells genetically modified to express a surface receptor, known as CAR, for the targeting of cognate antigens on specific cells. The effectiveness of CAR-T cell therapy in hematologic malignancies including leukemia, myeloma, and non-Hodgkin's lymphoma has led to consider its use as a potential avenue of treatment for autoimmune diseases. However, broadening the use of CAR-T cell therapy to a large spectrum of autoimmune conditions is challenging particularly because of the possible development of side effects including cytokine release syndrome and neurotoxicity. The design of CAR therapy that include additional immune cells such as double-negative T cells, γδ T cells, T regulatory cells and natural killer cells has shown promising results in preclinical studies and clinical trials in oncology, suggesting a similar potential utility in the treatment of autoimmune diseases. This review examines the mechanisms, efficacy, and safety of CAR approaches with a focus on their use in autoimmune diseases including systemic lupus erythematosus, Sjögren's syndrome, systemic sclerosis, multiple sclerosis, myasthenia gravis, lupus nephritis and other autoimmune diseases. Advantages and disadvantages as compared to CAR-T cell therapy will also be discussed.

Cite this paper

Formatted from the catalogue record. Check names, capitals and page numbers against the paper before you submit.

APA 7

Yu, J., Yang, Y., Gu, Z., Shi, M., La Cava, A., & Liu, A. (2024). CAR immunotherapy in autoimmune diseases: promises and challenges. Frontiers in Immunology, 15, 1461102. https://doi.org/10.3389/fimmu.2024.1461102

MLA 9

Yu, Jingjing, et al. “CAR immunotherapy in autoimmune diseases: promises and challenges.” Frontiers in Immunology, vol. 15, 2024, p. 1461102. https://doi.org/10.3389/fimmu.2024.1461102.

Chicago

Yu, Jingjing, Yi Yang, Zhanjing Gu, Min Shi, Antonio La Cava, and Aijing Liu. 2024. “CAR immunotherapy in autoimmune diseases: promises and challenges.” Frontiers in Immunology 15: 1461102. https://doi.org/10.3389/fimmu.2024.1461102.

Harvard

Yu, J. et al. (2024) ‘CAR immunotherapy in autoimmune diseases: promises and challenges’, Frontiers in Immunology, 15, p. 1461102. doi:10.3389/fimmu.2024.1461102.

IEEE

J. Yu, Y. Yang, Z. Gu, M. Shi, A. La Cava, and A. Liu, “CAR immunotherapy in autoimmune diseases: promises and challenges,” Frontiers in Immunology, vol. 15, p. 1461102, 2024, doi: 10.3389/fimmu.2024.1461102.

BibTeX

@article{yu2024immunotherapy,
  title     = {{CAR immunotherapy in autoimmune diseases: promises and challenges}},
  author    = {Yu, Jingjing and Yang, Yi and Gu, Zhanjing and Shi, Min and La Cava, Antonio and Liu, Aijing},
  journal   = {Frontiers in Immunology},
  year      = {2024},
  volume    = {15},
  pages     = {1461102},
  doi       = {10.3389/fimmu.2024.1461102},
  url       = {https://doi.org/10.3389/fimmu.2024.1461102}
}

Download for a reference manager: BibTeX (.bib) · RIS for Zotero, Mendeley and EndNote (.ris)

Citations by year

YearCitationsShare of the best year
202411
20251919
20261919

Its field-weighted citation impact is 1.74: it has been cited 1.74 times as often as the average work of the same field, type and year (1.00 is the world average).

Topic and keywords

Health Sciences › Medicine › Oncology › CAR-T cell therapy research

  • chimeric antigen receptor
  • CAR T-cell therapy
  • autoimmune disease
  • cytokine release syndrome
  • neurotoxicity
  • double-negative T cells
  • γδ T cells
  • regulatory T cells

Work with this paper

Most-cited papers in Medicine

All highly cited Medicine papers

Questions about this paper

How do I cite this paper in APA style?

Yu, J., Yang, Y., Gu, Z., Shi, M., La Cava, A., & Liu, A. (2024). CAR immunotherapy in autoimmune diseases: promises and challenges. Frontiers in Immunology, 15, 1461102. https://doi.org/10.3389/fimmu.2024.1461102

How many times has this paper been cited?

39 times, according to OpenAlex on 21 November 2026. Google Scholar and Scopus count different sets of sources, so their numbers differ.

Is this paper free to read?

Yes. It is open access at Frontiers in Immunology: sign in and open the PDF from this page.

Who wrote this paper?

Jingjing Yu, Yi Yang, Zhanjing Gu, Min Shi, Antonio La Cava, Aijing Liu.

What is the DOI of this paper?

10.3389/fimmu.2024.1461102, permanently at https://doi.org/10.3389/fimmu.2024.1461102. Sign in and open it from this page.

Bibliographic data from OpenAlex (CC0), last checked 21 November 2026. ResearchGuru does not host this paper; once you are signed in, the links open it at the publisher or the repository that does.